Valuation: Becton, Dickinson and Company

Market Cap 47.02B 40.73B 37.97B 34.92B 65.92B 4,471B 66.66B 446B 175B 2,237B 177B 173B 7,410B P/E 2026 *
37.2x
P/E 2027 * 24.2x
Enterprise Value 63.22B 54.75B 51.04B 46.94B 88.62B 6,011B 89.61B 600B 235B 3,008B 237B 232B 9,961B EV / Sales 2026 *
3.29x
EV / Sales 2027 * 3.08x
Free-Float
74.04%
Yield 2026 *
2.3%
Yield 2027 * 2.33%
Manager TitleAgeSince
Chief Executive Officer 53 2020-01-27
Director of Finance/CFO 44 2025-12-04
Compliance Officer - 2023-01-31
Director TitleAgeSince
Director/Board Member 75 2002-09-23
Director/Board Member 71 2010-07-25
Chairman 53 2021-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-5.43% - - 47.02B
+0.24%-2.12%-19.11%-1.80% 183B
-0.24%-1.77%-4.10%+2.32% 110B
+3.57%-0.44%+8.51%+71.16% 61.72B
-1.64%+6.86%+36.38%+52.45% 54.98B
+0.32%+1.34%-3.52%-36.98% 47.02B
-12.79%-8.52% - - 32.16B
-4.92%+10.01%+9.54%-31.31% 31.19B
+0.65%+4.02%+46.96%-6.41% 24.7B
-0.06%-0.90%+3.95%+2.96% 22.68B
Average -1.49%+1.40%+9.82%+6.55% 63.05B
Weighted average by Cap. -0.63%+0.19%-0.08%+8.21%

Financials

2026 *2027 *
Net sales 19.21B 16.64B 15.51B 14.27B 26.93B 1,827B 27.24B 182B 71.55B 914B 72.16B 70.57B 3,027B 19.72B 17.08B 15.92B 14.65B 27.65B 1,875B 27.96B 187B 73.44B 938B 74.08B 72.44B 3,108B
Net income 1.29B 1.12B 1.04B 958M 1.81B 123B 1.83B 12.24B 4.8B 61.36B 4.84B 4.74B 203B 1.98B 1.71B 1.59B 1.47B 2.77B 188B 2.8B 18.74B 7.36B 93.98B 7.42B 7.26B 311B
Net Debt 16.19B 14.03B 13.07B 12.02B 22.7B 1,540B 22.95B 154B 60.3B 770B 60.82B 59.48B 2,552B 13.82B 11.97B 11.15B 10.26B 19.37B 1,314B 19.58B 131B 51.45B 657B 51.89B 50.75B 2,177B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
170.66USD
Average target price
181.83USD
Spread / Average Target
+6.55%

Quarterly revenue - Rate of surprise